Chenhe Yi
Overview
Explore the profile of Chenhe Yi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Yi C, Cai N, Chen J
J Cancer Res Clin Oncol
. 2024 Nov;
150(11):487.
PMID: 39503880
Purpose: Highly complex tumor microenvironment makes hepatocellular carcinoma (HCC) as one of the most malignant tumors worldwide. The role of cellular senescence in HCC has been gradually recognized. The present...
2.
Yi C, Chen L, Tao B, Wang X, Lin J, Chen J
Hepatology
. 2024 Jul;
80(5):E71-E72.
PMID: 39018547
No abstract available.
3.
Chen Z, Shao W, Li Y, Zhang X, Geng Y, Ma X, et al.
Metabolism
. 2024 Jan;
152:155774.
PMID: 38191052
Background & Aims: Dysregulated cholesterol metabolism is the major factor responsible for cholesterol gallstones (CGS). Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in cholesterol homeostasis and its...
4.
Tao B, Yi C, Ma Y, Li Y, Zhang B, Geng Y, et al.
Biochem Genet
. 2023 Dec;
62(4):2999-3029.
PMID: 38062276
The transforming growth factor beta (TGF-β) signaling plays a critical role in immune evasion and tumor progression. However, its modulatory influences on prognosis, tumor microenvironment (TME), and therapeutic efficacy remain...
5.
Fan M, Chen Z, Shao W, Chen Y, Lin Z, Yi C, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2023 Jul;
55(9):1479-1486.
PMID: 37434430
Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular...
6.
Zhang B, Tao B, Li Y, Yi C, Lin Z, Ma Y, et al.
Eur J Intern Med
. 2023 Jan;
111:37-46.
PMID: 36588054
Background: Immune checkpoint inhibitor monotherapy did not show superiority of survival over standard therapy in advanced hepatocellular carcinoma. The combination immunotherapy including dual immune checkpoint inhibitors or combined with anti-VEGF...
7.
Zuo J, Yi C, Chen Z, Zhou B, Yang T, Lin J
Sci Rep
. 2022 Nov;
12(1):18384.
PMID: 36319832
Pyroptosis is an inflammatory form of cell death, which plays a key role in the development of auto-inflammation and cancer. This study aimed to construct a pyroptosis and inflammasome-related genes...
8.
He T, Tao B, Yi C, Zhang C, Zhang P, Shao W, et al.
Cancer Sci
. 2022 May;
113(8):2575-2589.
PMID: 35599597
Oxysterol metabolism plays an important role in the initiation and development of various tumors. However, little is known that the metabolic alternation can promote the metastasis of hepatocellular carcinoma (HCC)....
9.
Wang Y, Gao Y, Niu C, Wang B, Zhao S, Roex G, et al.
Cancer Immunol Immunother
. 2022 Apr;
71(11):2801-2814.
PMID: 35441325
Chimeric antigen receptor (CAR) T-cell therapy achieves great success for hematological malignancies. However, clinical trials have revealed some limitations in both improving the efficacy and reducing the relapse, which calls...
10.
Zhang B, Chen Z, Tao B, Yi C, Lin Z, Li Y, et al.
Mol Cancer
. 2021 Dec;
20(1):170.
PMID: 34930277
Recent studies have revealed the significant dysregulation of mA level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a biomarker for accurate screening of multiple...